戴納基 DYN 深滬

等待開盤 09-08 09:30:00 美东时间

24.28

-0.670

-2.69%

華盛通

立即下載

最高24.70
今開24.59
成交量 158.81万股
最低 24.14
昨收 24.95
總市值 45.34亿
52周最高 27.305
市盈率 ^靜 --
換手率 0.85%
52周最低 11.92
委比 7.72%
總股本 1.87亿
歷史最高 47.45
量比 0.86
振幅 2.24%
歷史最低 4.30
每手 1
風險率 3.63%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价

今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元

07-31 11:43
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $30 to $35.

07-31 01:43
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.75) by 44 percent. This is a 11.34 percent decrease over losses of $(0.97) per share from the same period last year.

07-30 05:33
财报速睇 | 戴纳基 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.79亿美元，同比亏损扩大61.1%

华盛资讯7月30日讯，戴纳基公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.79亿美元，同比亏损扩大61.1%。

07-30 04:47
财报速睇 | 戴纳基 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.79亿美元，同比亏损扩大61.1%

华盛资讯7月30日讯，戴纳基公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.79亿美元，同比亏损扩大61.1%。

07-30 04:19
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating.

07-23 21:49
Dyne Therapeutics Stock Tumbles After Hours: Here's Why

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares fell in after-hours trading Tuesday after the clinical-stage biotechnology company priced an upsized underwritten public offering of common stock. Shares of Dyne Therapeutics closed Tuesday’s regular session up 1.62% at $23.83 before falling 10.62% to $21....

07-22 13:52
TD Cowen Initiates Coverage On Dyne Therapeutics with Buy Rating

TD Cowen analyst Joseph Thome initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Buy rating.

06-27 00:39

派息除權日	每股總股息	派息日期
2002-05-30	0.08	2002-06-17
2002-02-27	0.08	2002-03-15
2001-11-29	0.08	2001-12-17
2001-08-29	0.08	2001-09-17
2001-05-29	0.08	2001-06-15
2001-02-27	0.08	2001-03-15
2000-11-29	0.08	2000-12-15
2000-08-29	0.08	2000-09-15
2000-05-26	0.15	2000-06-15
2000-02-24	0.04	2000-03-31
1999-12-01	0.01	1999-12-21
1999-09-01	0.01	1999-09-21
1999-06-01	0.01	1999-06-28
1999-03-04	0.01	1999-03-26
1998-12-01	0.01	1998-12-21
1998-09-01	0.01	1998-09-21
1998-05-28	0.01	1998-06-22
1998-03-09	0.01	1998-03-27
1997-12-01	0.01	1997-12-19
1997-08-22	0.01	1997-09-16
1997-05-21	0.01	1997-06-16
1997-02-13	0.01	1997-03-05
1996-11-27	0.01	1996-12-16
1996-07-25	0.01	1996-09-03
1996-05-16	0.01	1996-06-04
1996-03-21	0.01	1996-04-09
1995-12-14	0.01	1996-01-02
1995-09-21	0.01	1995-10-10
1995-06-16	0.01	1995-07-05
1995-03-01	0.01	1995-03-21
1994-12-01	0.01	1994-12-21
1994-08-31	0.01	1994-09-21
1994-06-01	0.01	1994-06-21
1994-03-01	0.01	1994-03-21
1984-10-03	0.66	1984-11-01
1984-07-03	0.66	1984-08-01
1984-04-04	0.66	1984-05-01
1984-01-04	0.66	1984-02-01
1983-10-03	0.62	1983-11-01
1983-07-05	0.62	1983-08-01
1983-04-05	0.62	1983-05-02
1983-01-04	0.62	1983-02-01
1982-10-04	0.62	1982-11-01
1982-07-02	0.62	1982-08-02
1982-04-02	0.62	1982-05-01
1982-01-05	0.62	1982-02-01
1981-10-05	0.60	1981-11-02
1981-07-06	0.60	1981-08-01
1981-04-06	0.60	1981-05-01
1981-01-05	0.60	1981-02-02
1980-10-06	0.60	1980-11-01
1980-07-03	0.60	1980-08-01
1980-04-02	0.57	1980-05-01
1980-01-03	0.57	1980-01-31
1979-10-02	0.57	1979-10-31
1979-07-02	0.57	1979-07-31
1979-04-03	0.57	1979-04-30
1979-01-03	0.57	1979-01-31
1978-10-02	0.57	1978-10-31
1978-07-02	0.57	1978-07-31
1978-04-03	0.57	1978-04-30
1978-01-03	0.57	1978-01-31
1977-10-02	0.55	1977-10-31
1977-06-30	0.55	1977-07-31
1977-04-03	0.55	1977-05-01

公司名稱	戴纳基
行業分類	电力
業務描述	Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

戴納基 DYN 深 滬

24.28

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

戴納基 DYN 深滬